Patients will present with a painful unilateral swelling in the vagina.
On examination, there will be a tender, erythematous swelling at 4 or 8 o’clock on the lateral vaginal wall. Tracking of the abscess along the vaginal wall may cause cellulitis.
We asked you in January to update to v4.7.2. After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.
To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.
To update to the latest release:
On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.
On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.
Welcome to the February 2025 update from the RDS team
A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:
The release will also incorporate a number of small fixes, including:
We will let you know when the date and time for the new release are confirmed.
There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.
The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.
Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.
At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .
We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.
Some important toolkits in development by the RDS team include:
The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.
To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)
To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form - also available in End-user and Provider sections of the RDS Learning and Support area. If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.
With kind regards
Right Decision Service team
Healthcare Improvement Scotland
To provide guidance on the management of those presenting with and Bartholin’s cyst or abscess
All healthcare professionals involved in the care of women with a Bartholin’s cysts or abscess
Please report any inaccuracies or issues with this guideline using our online form
The Bartholin’s gland is a mucus secreting gland located bilaterally at the base of the labia minora, at the level of the hymen. When the duct becomes blocked, a cyst may form and the gland may be palpable. If the cyst becomes infected, an abscess may form which can cause severe pain. The life-time risk is approximately 3%.
A charcoal swab should be obtained from the cyst/abscess and sent for culture and sensitivity. It is estimated that >70% of cysts are culture sterile, and only 33% of abscess cultures are sterile.
Bartholin’s duct abscesses may be polymicrobial: E. coli (single most common pathogen), followed by infections including Staphylococcus aureus, Group B streptococci and Enterococci species. Neisseria gonorrohoea may be identified.
Additional appropriate swabs should be obtained for chlamydia and gonorrohoea if there is risk of a sexually transmitted infection.
Biopsy
A biopsy may be indicated in women over 40 years old as there is an increased risk of adenocarcinoma of the Bartholin’s gland.
This will depend on the severity and the duration of the patient’s symptoms in addition to patient preference.
Recurrence rates are not consistently reported. However, one RCT (WoMan trial) summarised that Marsupialisation and Word catheter recurrence at 12 months are similar (10-12%). Where incision and drainage or needle aspiration is performed, recurrence is thought to be higher, and therefore should be avoided if possible. The aim should being to create a new mucocutaneous junction between the wall of the cyst and the skin of the labia to allow continued drainage.
Conservative management, no signs of infection
Hot baths several times per day and simple analgesia. In the absence of cellulitis, antibiotics are not indicated.
Conservative management, no surgical intervention with suggestion of mild infection with presence of cellulitis or offensive discharge. A review of any previous swabs should be undertaken.
Where antibiotic treatment is required, suggested regimes are
Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days
Or
Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)
Surgical Management - Word Balloon Catheter
This treatment should be used first line in the surgical management of Bartholin’s cysts or abscesses. This is a very well tolerated procedure and has good operative success.
The Word catheter kits contain the 3cm long catheter, a syringe for inflation and the scalpel. A local anaesthetic, such as 1% lidocaine, may be used to infiltrate the skin prior to the initial incision being made. Via a 5mm stab incision into the mucosal surface of the labia minora, just exterior to the hymen ring, within the introitus in the region of the normal duct opening.
A charcoal swab should be obtained from the discharging fluid.
The catheter is inserted and inflated with a maximum of 3ml of saline, as per the manufacturer’s guidelines. If the balloon is overfilled this may cause extra discomfort so the balloon should be deflated by extracting some saline. If the incision is made too large the catheter may fall out so an anchor suture may be required to hold it in place.
The patient can go home with the catheter in situ and usually this stays in for 4 weeks to encourage formation of an epithelialised fistula and prevent refilling of the abscess. A patient information leaflet should be given with a contact number for the gynaecology emergency service.
After 4 weeks, the catheter is deflated and removed. If the catheter falls out at home during this time it may be left out provided the patient’s symptoms are resolving.
Where there are no signs of infection, antibiotic cover is not required.
Consideration should be made to cover with broad spectrum antibiotics if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis. A review of any previous swab results should be undertaken.
Where antibiotic treatment is required suggest
Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days
or
Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)
Surgical Management - Marsupialisation
Where there is a recurrent abscess or if patient would prefer to avoid Word Catheter insertion, marsupialisation under a general anaesthetic should be performed. The purpose of this is to create a fistula and prevent further abscess formation. Packing is not routinely required.
In theatre, a single dose of intravenous antibiotic cover should be given.
1.2g of co-amoxiclav, IV
or
900mg of clindamycin, IV
Consideration should be made to continue cover with broad spectrum antibiotics, particularly if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis.
Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days
or
Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)
This is not routinely required after marsupialisation of the cyst or abscess.
If patients have already been commenced on oral antibiotics, they may wish to complete the course. However, they do not routinely need to start treatment after the initial dose in theatre, if there are no signs suggestive of infection.
Simple vulval hygiene advice should include avoiding bubble baths, lotions or talcum powder. Sexual intercourse should be avoided until there is no pain or discharge.